TABLE 5.

Votes on Other Benefits and Contextual Considerations for Oportuzumab Monataox

1 (suggests lower value)	2 (intermediate)	3 (suggests higher value)
Uncertainty or overly favorable model assumptions creates significant risk that base-case cost-effectiveness estimates are too optimistic	7 votes	Uncertainty or overly unfavorable model assumptions creates significant risk that base-case cost-effectiveness estimates are too pessimistic
2 votes		1 vote
1 (suggests lower value)	2 (intermediate)	3 (suggests higher value)
Very similar mechanism of action to that of other active treatments	3 votes	New mechanism of action compared to that of other active treatments
0 votes		7 votes
1 (suggests lower value)	2 (intermediate)	3 (suggests higher value)
Delivery mechanism or relative complexity of regimen likely to lead to much lower real-world adherence and worse outcomes relative to an active comparator than estimated from clinical trials	8 votes	Delivery mechanism or relative complexity of regimen likely to lead to much higher real-world adherence and better outcomes relative to an active comparator than estimated from clinical trials
0 votes		2 votes
1 (suggests lower value)	2 (intermediate)	3 (suggests higher value)
Will not significantly reduce the negative impact of the condition on family and caregivers vs the comparator	8 votes	Will significantly reduce the negative impact of the condition on family and caregivers vs the comparator
2 votes		0 votes